The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Compositions and methods can use a combination of thymol and/or carvacrol, optionally with high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of thymol and/or carvacrol, optionally with protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials.

Disclosed herein is a method for inhibiting coronavirus infection, including administering to a subject in need thereof an effective amount of rosiglitazone or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting coronavirus replication, including contacting a coronavirus with rosiglitazone or a pharmaceutically acceptable salt thereof.

There are provided methods for treating or preventing a cerebrovascular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isotope-enriched compound or a pharmaceutical composition thereof, where the isotope-enriched compound has the general Formula (I) or is a pharmaceutically acceptable salt or ester thereof:

R.sup.1R.sup.2X—CR.sub.2—CH.sub.2—CH.sub.2—SO.sub.3H  (I).

There are provided methods for treating or preventing a cerebrovascular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isotope-enriched compound or a pharmaceutical composition thereof, where the isotope-enriched compound has the general Formula (I) or is a pharmaceutically acceptable salt or ester thereof:

R.sup.1R.sup.2X—CR.sub.2—CH.sub.2—CH.sub.2—SO.sub.3H  (I).

The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective α-2 adrenergic receptor agonist.

The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective α-2 adrenergic receptor agonist.

The present invention relates to structured molecular vectors of formula (I), compounds of formula (II) and pharmaceutical compositions comprising such compounds. The invention also relates to such pharmaceutical compositions for use for preventing and/or treating a disease chosen among an inflammatory disease or a disease associated with a cognitive disorder. The invention further relates to such pharmaceutical compositions for use for preventing cognitive decline or restoring cognitive functions altered in brain injuries and/or in traumatic brain injuries and/or in a neuroinflammatory disease, and/or in a neurodegenerative disease.